RxDoctor Payments Data

Lynn Struck, MD

Neurology · Des Moines, IANPI 1750369344

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Lundbeck LLC at 27.8% of the total. Reporting peaked in 2020 at $3,585 and has fallen 97.5% since, to $88 in 2025.

$6,113in general payments, 2019–2025

Across 32 payments — averaging $191.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$2K
  • Medtronic$2K
  • Kyowa Kirin, Inc.$1K
  • AbbVie$704
  • Amneal Pharmaceuticals LLC$700
  • Teva Pharmaceuticals USA, Inc.$91
  • plus $192 from 6 others

What the payments were for

  • Consulting fees$63810%
  • Speaking & faculty fees$3,57058%
  • Travel & lodging$1,18219%
  • Food & beverage$63310%
  • Education$911%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,113 in reported general payments places this provider in the 85th percentile of 132 neurology providers in Iowa.

See all neurology providers in Iowa

Medicare billing

Part B allowed, 2024
$221,000
Medicare patients
970
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl148$651,684
NuplazidPimavanserin Tartrate55$283,672
RytaryCarbidopa/Levodopa176$148,156
IngrezzaValbenazine Tosylate11$92,903
Carbidopa-LevodopaCarbidopa/Levodopa2,734$82,986
Lamictal XrLamotrigine12$32,470
XadagoSafinamide Mesylate18$27,917
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone124$25,740
AmantadineAmantadine Hcl459$17,691
NeuproRotigotine15$16,365
Rasagiline Mesylate56$9,717
Carbidopa71$9,421
Entacapone66$8,770
Rivastigmine79$8,638
Carbidopa-Levodopa ErCarbidopa/Levodopa161$7,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$18$651,684148 claims
Amneal Pharmaceuticals LLCRytary$700$148,156176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 neurology providers in Iowa.

Other neurology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →